Manara - Qatar Research Repository
10.1007_s00296-021-04875-7.pdf (612.71 kB)

Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study

Download (612.71 kB)
journal contribution
posted on 2022-11-22, 21:12 authored by Mostafa Najim, Alaa Rahhal, Fadi Khir, Amer Hussien Aljundi, Safae Abu Yousef, Feryal Ibrahim, Aliaa Amer, Ahmed S. Mohamed, Samira Saleh, Dekra Alfaridi, Ahmed Mahfouz, Sumaya Alyafei, Faraj Howady, Mohamad Khatib, Samar A. Alemadi

Coronavirus disease 2019 (COVID-19) increases the risk of coagulopathy. Although the presence of antiphospholipid antibodies (aPLs) has been proposed as a possible mechanism of COVID-19-induced coagulopathy, its clinical significance remains uncertain. Therefore, this study aimed to evaluate the prevalence and clinical significance of aPLs among critically ill patients with COVID-19. This prospective observational study included 60 patients with COVID-19 admitted to intensive care units (ICU). The study outcomes included prevalence of aPLs, and a primary composite outcome of all-cause mortality and arterial or venous thrombosis between antiphospholipid-positive and antiphospholipid-negative patients during their ICU stay. Multiple logistic regression was used to assess the influence of aPLs on the primary composite outcome of mortality and thrombosis. A total of 60 critically ill patients were enrolled. Among them, 57 (95%) were men, with a mean age of 52.8 ± 12.2 years, and the majority were from Asia (68%). Twenty-two patients (37%) were found be antiphospholipid-positive; 21 of them were positive for lupus anticoagulant, whereas one patient was positive for anti-β2-glycoprotein IgG/IgM. The composite outcome of mortality and thrombosis during their ICU stay did not differ between antiphospholipid-positive and antiphospholipid-negative patients (4 [18%] vs. 6 [16%], adjusted odds ratio 0.98, 95% confidence interval 0.1–6.7; p value = 0.986). The presence of aPLs does not seem to affect the outcomes of critically ill patients with COVID-19 in terms of all-cause mortality and thrombosis. Therefore, clinicians may not screen critically ill patients with COVID-19 for aPLs unless deemed clinically appropriate.

Other Information

Published in: Rheumatology International
See article on publisher's website:



  • English


Springer Science and Business Media LLC

Publication Year

  • 2021

Institution affiliated with

  • Hamad Medical Corporation

Usage metrics

    Manara - Qatar Research Repository




    Ref. manager